Literature DB >> 20633528

miR-122-induced down-regulation of HO-1 negatively affects miR-122-mediated suppression of HBV.

Lipeng Qiu1, Hongxia Fan, Wensong Jin, Bao Zhao, Yanzhong Wang, Ying Ju, Lizhao Chen, Yu Chen, Zhongping Duan, Songdong Meng.   

Abstract

As the most abundant liver-specific microRNA (miRNA), miR-122 has been extensively studied for its role in the regulation of lipid metabolism, hepatocarcinogenesis and hepatitis C virus (HCV) replication, but little is known regarding its role in the replication of Hepatitis B virus (HBV), a highly prevalent hepatotropic virus that can cause life-threatening complications. In this study we examined the effects of antisense inhibition of miR-122 and transfection of a miR-122 mimic on HBV expression in hepatoma cells. The over-expression of miR-122 inhibited HBV expression, whereas the depletion of endogenous miR-122 resulted in increased production of HBV in transfected cells. We further found that the down-regulation of Heme oxygenase-1 (HO-1) by miR-122 plays a negative role in the miR-122-mediated inhibition of viral expression. Our study demonstrates the anti-HBV activity of miR-122, suggesting that therapies that increase miR-122 and HO-1 may be an effective strategy to limit HBV replication. Copyright (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20633528     DOI: 10.1016/j.bbrc.2010.07.021

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  60 in total

Review 1.  MicroRNAs and liver disease.

Authors:  Thomas A Kerr; Kevin M Korenblat; Nicholas O Davidson
Journal:  Transl Res       Date:  2011-02-02       Impact factor: 7.012

2.  Hepatitis B virus molecular biology and pathogenesis.

Authors:  R Jason Lamontagne; Sumedha Bagga; Michael J Bouchard
Journal:  Hepatoma Res       Date:  2016-07-01

Review 3.  microRNAs: fad or future of liver disease.

Authors:  Ashley M Lakner; Herbert L Bonkovsky; Laura W Schrum
Journal:  World J Gastroenterol       Date:  2011-05-28       Impact factor: 5.742

4.  Hepatobiliary quiz-8 (2013).

Authors:  Swastik Agrawal; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2013-12

Review 5.  Host functions used by hepatitis B virus to complete its life cycle: Implications for developing host-targeting agents to treat chronic hepatitis B.

Authors:  Bidisha Mitra; Roshan J Thapa; Haitao Guo; Timothy M Block
Journal:  Antiviral Res       Date:  2018-08-24       Impact factor: 5.970

Review 6.  Autophagy and microRNA in hepatitis B virus-related hepatocellular carcinoma.

Authors:  Shan-Ying Wu; Sheng-Hui Lan; Hsiao-Sheng Liu
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

7.  Inhibition of alpha interferon (IFN-α)-induced microRNA-122 negatively affects the anti-hepatitis B virus efficiency of IFN-α.

Authors:  Junli Hao; Wensong Jin; Xinghui Li; Saifeng Wang; Xiaojun Zhang; Hongxia Fan; Changfei Li; Lizhao Chen; Bin Gao; Guangze Liu; Songdong Meng
Journal:  J Virol       Date:  2012-10-10       Impact factor: 5.103

8.  Identification of suitable reference genes for qRT-PCR analysis of circulating microRNAs in hepatitis B virus-infected patients.

Authors:  Hai-Tao Zhu; Qiong-Zhu Dong; Guan Wang; Hai-Jun Zhou; Ning Ren; Hu-Liang Jia; Qing-Hai Ye; Lun-Xiu Qin
Journal:  Mol Biotechnol       Date:  2012-01       Impact factor: 2.695

9.  Clinical significance of circulating miR-122 in patients with dual chronic hepatitis B and C virus infection.

Authors:  Huei-Ru Cheng; Jia-Horng Kao; Hui-Lin Wu; Tai-Chung Tseng; Chen-Hua Liu; Hung-Chih Yang; Tung-Hung Su; Pei-Jer Chen; Ding-Shinn Chen; Chun-Jen Liu
Journal:  Hepatol Int       Date:  2014-11-18       Impact factor: 6.047

10.  Hepatitis B virus mRNA-mediated miR-122 inhibition upregulates PTTG1-binding protein, which promotes hepatocellular carcinoma tumor growth and cell invasion.

Authors:  Changfei Li; Yanzhong Wang; Saifeng Wang; Bo Wu; Junli Hao; Hongxia Fan; Ying Ju; Yuping Ding; Lizhao Chen; Xiaoyu Chu; Wenjun Liu; Xin Ye; Songdong Meng
Journal:  J Virol       Date:  2012-12-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.